Susquehanna International Group, LLP Galectin Therapeutics Inc Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

A detailed history of Susquehanna International Group, LLP transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Susquehanna International Group, LLP holds 81,467 shares of GALT stock, worth $216,702. This represents 0.0% of its overall portfolio holdings.

Number of Shares

81,467

Previous 202,335 59.74%

Holding current value

$216,702

Previous $457,000 50.98%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$2.04 - $2.86 $246,570 - $345,682	-120,868 Reduced 59.74%	81,467 $224,000
Q2 2024 Aug 15, 2024	SELL	$2.13 - $4.2 $335,519 - $661,588	-157,521 Reduced 43.77%	202,335 $457,000
Q1 2024 May 07, 2024	BUY	$1.6 - $2.44 $449,177 - $684,995	280,736 Added 354.82%	359,856 $860,000
Q4 2023 Feb 14, 2024	BUY	$1.6 - $2.18 $77,043 - $104,971	48,152 Added 155.49%	79,120 $131,000
Q3 2023 Nov 14, 2023	BUY	$1.38 - $1.97 $7,842 - $11,195	5,683 Added 22.48%	30,968 $59,000
Q2 2023 Aug 11, 2023	SELL	$1.32 - $2.08 $6,658 - $10,491	-5,044 Reduced 16.63%	25,285 $36,000
Q1 2023 May 16, 2023	SELL	$1.1 - $2.4 $18,566 - $40,509	-16,879 Reduced 35.75%	30,329 $63,000
Q4 2022 Feb 14, 2023	BUY	$1.03 - $1.66 $30,511 - $49,174	29,623 Added 168.46%	47,208 $53,000
Q3 2022 Nov 14, 2022	SELL	$1.31 - $2.48 $19,312 - $36,560	-14,742 Reduced 45.6%	17,585 $29,000
Q2 2022 Aug 15, 2022	SELL	$1.19 - $1.74 $57,278 - $83,751	-48,133 Reduced 59.82%	32,327 $42,000
Q1 2022 May 16, 2022	SELL	$1.61 - $2.31 $143,442 - $205,809	-89,095 Reduced 52.55%	80,460 $130,000
Q4 2021 Feb 14, 2022	BUY	$2.07 - $3.8 $143,316 - $263,093	69,235 Added 69.01%	169,555 $351,000
Q3 2021 Nov 15, 2021	SELL	$2.59 - $4.15 $91,142 - $146,038	-35,190 Reduced 25.97%	100,320 $389,000
Q2 2021 Aug 11, 2021	BUY	$2.07 - $5.1 $133,127 - $327,996	64,313 Added 90.33%	135,510 $434,000
Q1 2021 May 17, 2021	SELL	$1.96 - $2.57 $90,840 - $119,111	-46,347 Reduced 39.43%	71,197 $154,000
Q4 2020 Feb 16, 2021	SELL	$2.24 - $2.87 $27,247 - $34,910	-12,164 Reduced 9.38%	117,544 $263,000
Q3 2020 Nov 16, 2020	BUY	$2.53 - $3.64 $12,566 - $18,079	4,967 Added 3.98%	129,708 $347,000
Q2 2020 Aug 14, 2020	BUY	$1.66 - $3.15 $16,425 - $31,169	9,895 Added 8.62%	124,741 $382,000
Q1 2020 May 15, 2020	SELL	$1.51 - $3.0 $75,999 - $150,993	-50,331 Reduced 30.47%	114,846 $225,000
Q4 2019 Feb 14, 2020	SELL	$2.79 - $4.32 $84,492 - $130,826	-30,284 Reduced 15.49%	165,177 $472,000
Q3 2019 Nov 14, 2019	SELL	$3.0 - $4.05 $502,041 - $677,755	-167,347 Reduced 46.13%	195,461 $717,000
Q2 2019 Aug 16, 2019	BUY	$3.61 - $5.0 $9,732 - $13,480	2,696 Added 0.75%	362,808 $1.51 Million
Q2 2019 Aug 14, 2019	SELL	$3.61 - $5.0 $304,889 - $422,285	-84,457 Reduced 19.0%	360,112 $1.49 Million
Q1 2019 May 15, 2019	BUY	$3.86 - $6.02 $1.09 Million - $1.69 Million	281,460 Added 172.56%	444,569 $2.27 Million
Q4 2018 Feb 14, 2019	SELL	$3.43 - $5.74 $991,952 - $1.66 Million	-289,199 Reduced 63.94%	163,109 $559,000
Q3 2018 Nov 14, 2018	BUY	$3.68 - $6.93 $347,815 - $654,988	94,515 Added 26.42%	452,308 $2.72 Million
Q2 2018 Aug 14, 2018	BUY	$3.16 - $9.16 $961,676 - $2.79 Million	304,328 Added 569.21%	357,793 $2.28 Million
Q1 2018 May 15, 2018	SELL	$3.78 - $5.97 $62,407 - $98,564	-16,510 Reduced 23.59%	53,465 $253,000
Q4 2017 Feb 14, 2018	SELL	$1.54 - $3.34 $151,956 - $329,567	-98,673 Reduced 58.51%	69,975 $234,000
Q3 2017 Nov 14, 2017	BUY	$1.67 - $2.3 $281,642 - $387,890	168,648	168,648 $358,000

Others Institutions Holding GALT

# of Institutions

Shares Held

9.44M

Call Options Held

1.16M

Put Options Held

1.98M

View Full List

About GALECTIN THERAPEUTICS INC

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $158M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

More about GALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Galectin Therapeutics Inc Transaction History